Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) Director Sells $167,152.80 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction on Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the transaction, the director owned 40,418 shares in the company, valued at $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bernadette Connaughton also recently made the following trade(s):

• On Wednesday, July 1st, Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $76.71, for a total value of $124,653.75.
• On Monday, June 1st, Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $66.21, for a total value of $107,591.25.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO remained flat at $102.62 during mid-day trading on Tuesday. The company had a trading volume of 2,845,965 shares, compared to its average volume of 1,862,276. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $104.78. The company has a market capitalization of $12.17 billion, a price-to-earnings ratio of 30.63, a PEG ratio of 0.43 and a beta of 0.85. The stock’s 50 day simple moving average is $77.17 and its 200 day simple moving average is $71.70. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.49. The business had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, research analysts predict that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

Institutional Trading of Halozyme Therapeutics

A number of institutional investors have recently bought and sold shares of HALO. Norges Bank purchased a new position in shares of Halozyme Therapeutics during the 4th quarter worth about $128,201,000. William Blair Investment Management LLC bought a new stake in Halozyme Therapeutics in the fourth quarter worth about $124,031,000. Voloridge Investment Management LLC purchased a new position in shares of Halozyme Therapeutics during the third quarter valued at approximately $77,587,000. Qube Research & Technologies Ltd bought a new position in shares of Halozyme Therapeutics during the second quarter valued at approximately $51,295,000. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Halozyme Therapeutics by 4,578.9% in the second quarter. Assenagon Asset Management S.A. now owns 997,643 shares of the biopharmaceutical company’s stock worth $78,086,000 after buying an additional 976,321 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on HALO shares. Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $83.00 to $110.00 in a research note on Friday. Morgan Stanley dropped their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday. Citizens Jmp lifted their price objective on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a research report on Friday. Finally, Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $91.20.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.